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Background. To explore the application of serum proteomic patterns for the preoperative detection of regional lymph node
involvement of colorectal cancer (CRC). Methods. Serum samples were applied to immobilized metal aﬃnity capture ProteinChip
to generate mass spectra by Surface-Enhanced Laser Desorption/ionization Time-of-Flight Mass Spectrometry (SELDI-TOF-MS).
Proteomic spectra of serum samples from 70 node-positive CRC patients and 75 age- and gender-matched node-negative CRC
patients were employed as a training set, and a classiﬁcation tree was generated by using Biomarker Pattern Software package. The
validity of the classiﬁcation tree was then challenged with a blind test set including another 65 CRC patients. Results. The software
identiﬁed an average of 46 mass peaks/spectrum and 5 of the identiﬁed peaks at m/z 3,104, 3,781, 5,867, 7,970, and 9,290 were
usedtoconstructtheclassiﬁcationtree.Theclassiﬁcationtreeseparatedeﬀectivelynode-positiveCRCpatientsfromnode-negative
CRC patients, achieving a sensitivity of 94.29% and a speciﬁcity of 100.00%. The blind test challenged the model independently
witha sensitivityof 91.43% a speciﬁcity of 96.67%.Conclusions. Theresults indicate thatSELDI-TOF-MScan correctly distinguish
node-positive CRC patients from node-negative ones and show great potential for preoperative screening for regional lymph node
involvement of CRC.
1.Introduction
Pathologic stage represents the most important prognostic
factor for patients with colorectal carcinomas (CRCs) [1, 2].
It has been shown that many regional lymph node involve-
mentsinCRCarefoundwiththemodeofsmalllymphnodes
(less than 5mm in diameter) [3, 4], and standard pathologic
evaluationmayoverlooktheselow-volumenodalmetastases,
thereby failing to identify nodes imperative to accurate
staging. Therefore, it is extremely necessary to understand
the molecular alterations, which confer a regional lymph
node involvement and then use this information to enhance
node-staging accuracy and individual patient management.
Because of the marked heterogeneity of CRC, a panel of
biomarkers for screening and diagnosis would be most app-
ropriate.Surface-enhancedlaserdesorption/ionizationtime-
of-ﬂight mass spectrometry (SELDI-TOF-MS), an aﬃnity-
based mass spectrometry method using a protein chip
modiﬁed with a speciﬁc chromatographic surface, is a modi-
ﬁed matrix-assisted laser desorption/ionization mass system,
overcoming many of the limitations of 2-dimensional ele-
ctrophoresis and matrix-assisted laser desorption/ionization
TOF mass spectrometry [5, 6]. This advanced and smart
technique’s practical application, as to analysis of complex
biologic specimens such as cell lysates, serum, and body ﬂu-
ids, can detect multiple protein changes simultaneously with
high sensitivity and speciﬁcity [5–9]. In recent years, several
groups had investigated serum samples from CRC patients
and controls to construct patterns for identiﬁcation of CRC
patients from healthy controls with high sensitivity and
speciﬁcity by using SELDI-TOF-MS and diﬀerent protein
chips[10,11].Theaimofthecurrentstudywastoinvestigate
the application of serum SELDI protein proﬁling for the
preoperative detection of regional lymph node involvement
state of CRC.
2. MatreialsandMethods
2.1. Patients and Serum Samples. A total of 210 serum
samples (including pathologically conﬁrmed node-positive
CRC patients and node-negative patients 105 cases) were2 Gastroenterology Research and Practice
collected preoperatively from the institute of anal-colorectal
surgery of 150th hospital of People’s Liberation Army (PLA)
from October 2006 to March 2008. The study was approved
by the Research Ethics Committee of 150th Hospital PLA,
and all CRC patients involved in the study signed an
agreementformconsentingforthedonatingtheirspecimens.
All patients, diagnosed as colorectal sporadic moderately
diﬀerentiated adenocarcinoma by postoperative pathology
examination, were found to have no evidence of other
diseases. The distribution of clinical stages (AJCC, 2004)
were as follows: 31 cases were at stage I, 58 stage IIa, 16
stage IIb, 8 stage IIIa, 84 stage IIIb, and 13 stage IIIc (AJCC,
2004). The average age of the Node-positive CRC patients
(49 men, 56 women ranging from 31 to 82 years) was 58.4
years and that of node-negative CRC patients (51 men, 54
women ranging from 29 to 78 years) was 56.4 years. The
node-positive CRC patients and node-negative patients are
age- and gender-matched. Using a case-control study design,
the samples were then separated into training set and test set
according to the collected date. The training set (including
70 sera from node-positive CRC patients, and 75 from node-
negative CRC patients) were collected from October 2006
to September 2007, and the test set (including 35 sera from
node-positiveCRCpatients,and30fromnode-negativeCRC
patients) were collected from October 2007 to March 2008.
As pooling serum samples may lead to loss of potential
biomarkers in SELDI-TOF-MS proteomic proﬁling [12],
quality control sample was oﬀered by a healthy volunteer
(male, 42 years old). The quality control serum sample was
used to determine reproducibility and treated as a control
protein proﬁle for each SELDI-TOF-MS experiment.
Two milliliters of whole blood were collected by veni-
puncture into a vacuum tube in the morning before food
i n t a k e( t w od a y sb e f o r eo p e r a t i o n )t h e nw e r ed e p o s i t e dt o
clot at 4◦C for 2 hours. The blood was later centrifuged for
20min at 700g, aliquoted into 100μL, and frozen for storage
at −80◦C until used.
2.2. SELDI-TOF-MS Protein Analysis. The IMAC30 array,
which is suitable for this work [13], was assembled in 8-well
ProteinChip Bioprocessor, pretreated with 50μL 100mM
CuSO4 to each well for 5 minutes at room temperature,
washed 5 times with 50μL distilled water, then incubated
with 50μL neutralizing buﬀer (100mM NaAc, pH4) on
a platform shaker for 5 minutes, and washed with 50μL
distilled water for 5 times. After being equilibration with
binding buﬀer (100mmol/L sodium phosphate, 500mmol/L
sodium chloride, pH7.0), the IMAC30 array was chelated
with copper for capturing copper-binding proteins through
histidine, tryptophan, cysteine, or phosphorylated amino
acids. Serum samples were diluted 1:3 into U9 buﬀer (9M
urea, 2%CHAPS, 50mM Tris-HCl, pH 9.0) and incubated
on ice for 30 minutes. Then the diluted samples were diluted
1:13 with the U9 buﬀer. Each array spot was loaded with
50μL of diluted serum sample with the 8-well ProteinChip
Bioprocessor. After incubated in a platform shaker at room
temperature for 60 minutes and the unbounded sample
being discarded, each spot was equilibrated with the binding
buﬀer (50μL/spot) twice (5 minutes per time) to remove
the nonspeciﬁc binding proteins. The array was then quickly
rinsed with 150μL of distilled water before air-drying. Each
s p o tw a sl o a d e dw i t h0 . 5 μL of saturated sinapinic acid
solution prepared in 50% (vol/vol) acetonitrile and 0.5%
(vol/vol) triﬂuoroacetic acid. After air-drying, sinapinic acid
solution was added again. Then the array was read by Pro-
teinChip reader. Amount of 31 protein chip arrays were done
one by one as mentioned above for the analysis of samples.
During experiments, the quality control serum sample was
used to test the reproducibility of a single IMAC30 chip
(intraassay) and that between chips (interassay).
ThePBS-II(c)ProteinChipreaderwascalibratedwiththe
“All-in-one” peptide standard (Ciphergen Biosystems). Each
spot was scanned by a laser with the intensity of 200 and
a detector with the sensitivity of 9. Mass-to-charge (m/z)
ratio was optimized from 2,000 to 20,000, with a maximum
of 150,000. The selected sample spots were exposed to the
laserbeamat15 diﬀerent positions, 7 spots foreach position.
The TOF mass spectra were then collected using Ciphergen’s
ProteinChip Software 3.1.
2.3. Bioinformatics and Biostatistics. The entire dataset was
separated into training set and test set before analysis. The
training set was used to construct the classiﬁcation tree,
which was consisted of spectra data from 75 node-negative
CRCpatientsandage-andgender-matched70node-positive
patients.Thetestset,whichwasconsistedoftheotherspectra
data of 35 node-positive patients and age- and gender-
matched30node-negativepatients,wasusedtochallengethe
discriminatory ability of the classiﬁcation algorithm blindly.
A l ls p e c t r a ld a t aw e r en o r m a l i z e db yt o t a li o nc u r r e n t
after background subtraction. The range of peak masses was
settledbetweenm/z2,000and20,000becausethemajorityof
resolved protein/peptides were found in this range. The m/z
from0to2,000wasexcludedfromanalysisbecausetheywere
mainly the signal noises of the energy-absorbing molecule.
The Biomarker Wizard Software (Ciphergnen Biosystems)
wassubsequentlyusedtomakepeakdetectionandclustering
across all spectra in the training set and test set with the
following settings—for peak detection, the signal-to-noise
ratio was 3 and minimum peak threshold was 20%, while
for cluster completion, the cluster was 0.5% and the signal-
to-noise ratio for the second pass was 2. The spectral data
were then exported as spreadsheet ﬁles. The spectral data
of training set were further analyzed by the Biomarker
Pattern Software (version 4.0; Ciphergnen Biosystems) to
develop a classiﬁcation tree. The classiﬁcation tree was set
up to divide the training dataset into node-positive CRC
patientsandnode-negativepatientsthroughmultiplerounds
of decision-making in training mode. When the dataset was
ﬁrst transferred to Biomarker Pattern Software, the dataset
formed a “root node”. Based on intensity, the software tried
to ﬁnd the best peak to separate this dataset into 2 “child
nodes”. To achieve this, the software would identify the
peak and set the concerning intensity threshold. If the peak
intensityofablindsamplewasnothigherthanthethreshold,
this peak would go to the left-side child node; otherwise
the right-side. The process would go on for each child node
until a blind sample entered a terminal node, either labelledGastroenterology Research and Practice 3
as node-positive patients or node-negative patients. Peaks,
which were selected during the process to form the model,
were the ones that yielded the least classiﬁcation error when
being combined to be used. After cross-validation in test
mode, the validity of this decision tree was further veriﬁed
using the test set data blindly, which is independent of the
training set.
2.4. Statistical Analysis. Comparison of relative peaks inten-
sity levels between groups was made by using the Student t-
test and in all cases P<10
−4 was considered, statistically, sig-
niﬁcant.Comparisonofratesbetweengroupswasconducted
using the χ2 test and P<0.05 was regarded as a signiﬁcant
diﬀerence.
3. Results
3.1. Serum SELDI Proﬁles of CRC with Regional Lymph
Node Involvement versus CRC without Regional Lymph
Node Involvement. Spectra from 145 serum samples of
CRC patients were acquired in the training set. The pro-
tein peaks were identiﬁed with masses from m/z 2,000
to 20,000, and 46-peak cluster or common peaks were
generated from the identiﬁed peaks using the Biomarker
Wizard Software. It was found that most of the peaks
were detected between m/z 3,000 and 16,500, and the
comparability among diﬀerent samples showed that over-
all serum proﬁles from node-positive CRC patients and
node-negative patients were very similar despite a few
of intersample variations. Therefore, the variations that
consistently diﬀerentiate these 2 diﬀerent groups could
be considered as the biomarkers of node-positive CRC
patients and were considered the most useful for protein
proﬁling. As peaks data from the training set were saved
and exported for pattern recognition by Biomarker Pattern
Software, a classiﬁcation tree was created thereby from
the training set to discriminate the node-positive CRC
patients from node-negative patients. Figure 1 represents the
spectral views showing these protein peaks at m/z 7,970
in these 2 groups. From the quantitative point of view,
the average normalized intensities of these proteins were
either over- or low expressed in node-positive CRC patients
(Table 1). These diﬀerence were statistically signiﬁcant (P<
0.05).
Among these classiﬁcation trees generated by adjusting
the setting of Gini, costs, advance, and testing of Biomarker
Pattern software, the optimal classiﬁcation tree with the
lowest error cost was eventually established. The selected
classiﬁcation tree is simple and straightforward and used
2 splitters (Node 1 and Node 2) with distinct masses
of m/z 3,104, 3,781, 5,867, 7,970, and 9,290, respectively,
and classiﬁed 3 terminal nodes (Figure 2). The variable
importance score of some peaks were shown in Table 2.T h e
error rate of the generated classiﬁcation tree was estimated
through a process of cross-validation.
Performance of the generated classiﬁcation tree is sum-
marized for the training and test sets. For training set part,
the classiﬁcation algorithm was ﬁrstly challenged on learning
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Figure 1: Representative serum protein proﬁling spectra of node-
positive CRC patients and node-negative CRC patients. The peaks
at m/z 7,970 were compared. m/z represents the mass to charge
ratio.
mode and achieved an accuracy of 100.00% (145 of 145);
secondly it was cross-validated on test mode and achieved
an accuracy, sensitivity, and speciﬁcity of 97.24% (141 of
145),94.29%(66of70),and100.00%(75of75),respectively.
The validity and accuracy of the classiﬁcation algorithm
were then evaluated by challenging to classify blinded objects
correctly in the test set. The algorithm correctly classiﬁed
93.85% (61 of 65) of the total testing samples with a
sensitivity of 91.43% (32 of 35), a speciﬁcity of 96.67% (29
of 30), and a positive predictive value of 96.97% (32 of 33)
(Table 3).
3.2. Quality Control and Reproducibility. The reproducibility
of each SELDI protein chip assay spectra, that is, mass and
intensity from array to array on a single IMAC30 chip (intra-
assay) and between chips (interassay), was determined by
the one healthy volunteer serum sample. Three proteins,
among the range of m/z 3,000 to 10,000 observed on spectra
randomly selected over the course of the study, were used
to calculate the coeﬃcient of variance (CV). The intra- and
interassay CVs for mass were both 0.03% while the intra-
and interassay CVs for the normalized intensity were 17.20%
and 19.48%, respectively. Little variations with day-to-day
sampling and instrumentation or chip variations were also
found.
4. Discussion
The causative reason of the death of CRC is associated
directly with stage and therapeutic methods. Presence and
extent of regional lymph node involvement predict outcome
in patients with CRC. In terms of diagnosis, treatment,
and survival in patients, completeness of nodal resection
and staging accuracy has signiﬁcant implications with this
disease [14]. Up to 30% of patients with node-negative4 Gastroenterology Research and Practice
Node 1
m/z 3104, 3781,
5867, 7970, 9290
N = 145
Node 2
m/z 3781, 5867
N = 77
Terminal node 1
N = 2
Terminal node 2
N = 75
Terminal node 3
N = 68
Figure 2: The pattern-matching algorithm to distinguish node-positive CRC patients from node-negative CRC patients on learning mode
of training set. The left branch node after Node 1 is the cases of the linear combination: −0.075 (m/z 3,104) −0.231 (m/z 3,781) + 0.157
(m/z 5,867) + 0.086 (m/z 7,970) + 0.953 (m/z 9,290) ≤1.122, and the right one is >1.122. The left branch node after the Node 2 is the linear
combination: 0.410 (m/z 3,781) −0.912 (m/z 5,867) ≤0.248, and the right one is >0.248. The cases met to the conditions of Terminal Node
1 and Terminal Node 3 were diagnosed as node-positive CRC patients, and those met to the conditions of Terminal Node 2 were diagnosed
as node-negative CRC patients. N represents the number of samples. m/z represents the mass to charge ratio.
Table 1: SELDI protein peak intensities in serum with signiﬁcant diﬀerences (P<0.05) between node-positive CRC patients and node-
negative CRC patients.
Peak, m/z Protein quantiﬁcation (x ±SD) TP
Node (+) Node (−)
5,867 3.534 ±0.547 0.230 ±0.107 58.749 0
9,290 3.271 ±0.587 1.443 ±0.103 73.932 0
7,970 12.364 ±1.08 7.913 ±0.668 61.235 1E −10
14,433 0.891 ±0.168 0.404 ±0.102 42.436 1.8E −09
15,621 1.782 ±0.609 5.873 ±0.655 23.125 2.16E −08
15,824 0.729 ±0.111 2.072 ±0.255 20.218 4.25E −08
13,652 1.388 ±0.168 2.423 ±0.259 26.276 7.58E −07
3,781 4.268 ±0.216 6.799 ±0.977 33.346 9.28E −07
15,006 0.641 ±0.150 1.824 ±0.084 19.552 2.26E −06
7,802 6.580 ±0.504 5.170 ±0.635 16.319 5E −05
4,497 9.154 ±0.639 5.139 ±0.916 22.740 0.000106
7,504 0.034 ±0.005 0.704 ±0.271 10.960 0.000106
5,967 8.809 ±0.705 6.021 ±0.879 18.793 0.000124
5,808 4.947 ±0.797 2.252 ±0.990 19.989 0.001097
10,057 1.809 ±0.301 1.206 ±0.245 8.139 0.001261
7,597 44.557 ±1.121 37.993 ±1.763 13.041 0.001549
5,786 16.269 ±1.880 11.966 ±0.994 10.461 0.003002
15,089 0.708 ±0.198 1.678 ±0.042 7.895 0.003002
3,104 4.719 ±0.478 6.626 ±0.791 7.436 0.012677
14,869 1.922 ±0.653 4.278 ±1.079 6.209 0.0134
7,620 12.534 ±2.920 8.908 ±1.474 13.036 0.017595
5,662 1.760 ±0.601 0.266 ±0.131 12.497 0.035988
Peaks were named by their mass to charge ratio (m/z).
CRC staged by standard pathologic techniques ultimately
suﬀer from disease recurrence and tumor-related mortality
following potentially curative primary resection. Tradition-
ally, the methods of local staging for CRC include digital
rectal assessment, proctoscopy, transrectal ultrasonography
(TRUS), pelvic computed tomography (CT), and magnetic
resonance imaging (MRI). More recently, positron emission
tomography has also been taken into consideration. In spite
of numerous studies and meta-analyses being performed
not only for comparing the performance of these stagingGastroenterology Research and Practice 5
Table 2: Important peaks selected by the biomarker pattern soft-
ware.
Peak, m/z Score∗
5,867 100.00 ||||||||||||||||||||||||||||||||||||||||||
9,290 100.00 ||||||||||||||||||||||||||||||||||||||||||
7,970 78.81 |||||||||||||||||||||||||||||||||
15,823 67.55 ||||||||||||||||||||||||||||
15,621 63.21 ||||||||||||||||||||||||||
Peaks were named by their mass to charge ratio (m/z).
∗The most important peak was assigned an importance index of 100. The
importance of other peaks was compared with the top peak and a number
b e l o w1 0 0w a sg i v e nf o re a c hp e a k .
Table 3: Performance of the classiﬁcation tree analysis of node-
positive CRC patients in training set and test set.
Sets Sensitivity
(%)
Speciﬁcity
(%)
Accuracy
rate (%)
Training set
Learning mode 100.00%
(70/70)
100.00%
(75/75)
100.00%
(145/145)
Test mode 94.29%
(66/70)
100.00%
(75/75)
97.24%
(141/145)
Test set 91.43%
(32/35)
96.67%
(29/30)
93.85%
(61/65)
Number in parentheses denotes the number of correctly classiﬁed samples
of the total number of samples in the group.
modalitiesalltogetherbutalsoforspeciﬁcparameters(Tand
N stage, circumferential margin), no general agreement has
been achieved [15–17].
The molecular and cellular heterogeneity of CRC results
in the expression variety of tumor cell products. Analysis
of the resultant protein proﬁle may have greater eﬃciency
in node-staging by selecting a combination of protein
alterations (pattern recognition) rather than by focusing on
speciﬁc tumor marker. Evaluations of conventional serologic
markers, such as CEA and CA19-9, have yielded confusing
results with poor sensitivity and speciﬁcity for use in early
detection. To our knowledge, these biomarkers have not yet
been used in node-staging.
Two-dimensional gel electrophoresis has traditionally
been used to identify diﬀerences in protein expression in
terms of serum, saliva, or tissue specimens, with identiﬁed
proteins subsequently being excised from the gel and being
subjected to peptide mapping analysis by mass spectrometry,
which is used for the identiﬁcation of proteins [18, 19].
However, it is labor and time intensive that can be hardly to
be reproduced. Besides this, its character conﬁnes itself for
not being able to handle proteins with molecular weights of
less than 10kDa. SELDI-TOF-MS is able to generate high-
throughputproteinproﬁlethatcanafterwardsbeanalyzedto
tell protein patterns diﬀerencesbetweenpatientswithdisease
and healthy controls; even it can be used to distinguish
patients with diﬀerent disease stage. Proteomic analysis of
serum samples from patients with pancreatic, gastric, breast,
nasopharyngeal, liver, ovarian, prostate, and colorectal can-
cer using SELDI-TOF-MS has been approved feasibility to
identify reproducible protein proﬁle that is associated with
speciﬁc tumor biomarkers, which can deﬁnitely be used for
early detection of disease [5–9].
Currently, we attempt to combine the SELDI protein
chip technology and an artiﬁcial intelligence classiﬁcation
algorithm to screen serum protein spectra in the Chinese
populationofnode-positiveCRCpatientsandnode-negative
patients. For the training set, all 145 serum samples were
used to proﬁle protein peaks and to detect important peaks.
With a panel of 5 peaks, a classiﬁcation and regression tree
was set up by using Biomarker Pattern Software, which
yielded a sensitivity of 94.29% and a speciﬁcity of 100%
in diﬀerentiating node-positive CRC patients from node-
negative patients. Furthermore, the blind test challenged the
model with a sensitivity of 91.43% (32 of 35), a speciﬁcity of
96.67% (29 of 30), and a positive predictive value of 96.97%
(32 of 33).
Regarding the study of serum biomarkers for CRC, Chen
et al. [10] investigated in 55 serum samples from patients
with CRC and 92 healthy individuals with corresponding
physiological features by using H4 protein chips and SELDI-
TOF-MS. The analysis software (artiﬁcial neural network
classiﬁer) separated CRC from healthy individuals, with
a sensitivity of 91% and speciﬁcity of 93%. Four top-
scored peaks at m/z of 5,911, 8,930, 8,817, and 4,476, were
ﬁnally selected as the potential “ﬁngerprints” for detection
of CRC. Liu et al. [11] used SELDI protein chip (IMAC3)
arrays to screen both patients with CRC and health people.
The Biomarker Wizard and Biomarker Pattern Software
packages were also applied and then constructed a pattern
with 2 protein peaks, achieving a sensitivity of 95.00% and
speciﬁcity of 94.87%, respectively, in masked analysis of an
independent set of serum samples. As for staging of CRC,
Xu et al. [20] detected the serum proteomic pattern by
using SELDI-TOF-MS technology and CM10 protein chip
in CRC. They built up a model formed by 6 protein peaks
(m/z 2,759, 2,964, 2,047, 4,795, 4,139, and 37,761), which
could distinguish local CRC patients (stage I and stage II)
from regional CRC patients (stage III). By comparison, the
serum biomarkers they found were quite diﬀerent; this may
be due to diﬀerent types of chips they used and the patients
included.
As serum protein proﬁle alternates with the development
of cancer, we deem that there must be some proteins
representing the characteristic of lymph node involvement
of CRC. Considering that IMAC30-Cu2+ chips are the
improvement of IMAC3-Cu2+ chips and sporadic moder-
ately diﬀerentiated adenocarcinoma accounts for about 50%
of all CRC, we studied lymph node stage of the colorectal
sporadic moderately diﬀerentiated adenocarcinoma using
IMAC30-Cu2+ chips.
Also, we compared the sensitivity and speciﬁcity of the
classiﬁcation tree we built up and those of TRUS and MRI
reported in lectures, the former surpass the later.
The present work explored a panel of highly sensitive
and speciﬁc serum biomarkers using the SELDI protein
chip technology, combining with an artiﬁcial intelligence6 Gastroenterology Research and Practice
classiﬁcation algorithm. The model could classiﬁy node (+)
patients of colon cancer and rectum cancer from the node
(−) ones with a sensitivity close to 100%. These results
suggested that the diagnosis ability of the model plays high
sensitivity and speciﬁcity in classifying both colon cancer
and rectum cancer. Although, these biomarkers provide a
potential diagnostic platform for CRC node-staging, which
need conformation and reproducibility by much larger and
more detailed dataset, the point is that such an innovative
clinical diagnostic method has the potential to improve the
preoperative node-staging and optimize the individual man-
agement of CRC. The 22 protein peaks, either over- or low
expressedinCRCwithregionallymphnodeinvolvement,are
now being identiﬁed by HPLC and MALDI-MS-MS in our
laboratory.
In brief, the serum protein proﬁling using SELDI-TOF-
MS could diﬀerentiate CRC with regional lymph node
involvement from patients without regional lymph node
involvement with a higher degree of sensitivity, speciﬁcity,
and accuracy. This pioneering technology will doubtless
enjoy a promising development room for ﬁguring out CRC
preoperative node-staging, eﬃciently and veraciously.
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